{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117116","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.844326+00:00","generated_at":"2026-06-22T00:05:10.699887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical Q3 revenue down 18% to $16.1M; net loss $10.1M; DFD-29 Phase 3 75% enrolled","bullets":["Revenue $16.1M in Q3 2022 versus $19.6M in Q3 2021, decline due to Targadox generic competition.","Net loss $10.1M ($0.57/sh) vs $10.6M ($1.16/sh); Non-GAAP Adj EBITDA loss $4.0M vs +$1.3M.","DFD-29 Phase 3 studies 75% enrolled; top-line data expected H1 2023, NDA filing H2 2023.","Nine-month revenue up 26% to $57.7M; CEO expects record full-year 2022 revenue.","Company expects to launch another product in the upcoming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117116","json":"https://secwatch.observer/filing/0001104659-22-117116.json","markdown":"https://secwatch.observer/filing/0001104659-22-117116.md","text":"https://secwatch.observer/filing/0001104659-22-117116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/0001104659-22-117116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/tm2230077d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:05:10.699887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa323ced58c5dd1ebbe4f1b60a29ba16ecf0cdb4","claim":"Journey Medical Corp reported the third quarter and nine months ended September 30, 2022 results: revenue $16.1 million, net income ($10.1) million, EPS ($0.57) per share basic and diluted.","evidence_excerpt":"position Journey Medical for sales growth in the coming years. Journey Medical also expects to launch another product in the upcoming months.” Financial Results: · Revenues were $16.1 million for the third quarter of 2022, compared to revenues of $19.6 million for the third quarter of 2021, representing a decline of $3.5 million. The decline in revenue was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/0001104659-22-117116-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter and nine months ended September 30, 2022"},{"label":"Revenue","value":"$16.1 million"},{"label":"Net income","value":"($10.1) million"},{"label":"EPS","value":"($0.57) per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}